When: Price reaches $59.71 with 1/3 of re-deployment capital available

Then: Re-enter final 1/3 of trimmed position

When: BMY closes above $68.10 on >15M shares with MACD bullish re-cross before revisiting entry levels

Then: Redeploy 50% of trimmed capital at breakout confirmation rather than waiting indefinitely

SELL (trim 30-40% at $66, retain 60% position)

• Verified close is $66.05, not the unverified $67.61 print from 2026-08-19
• MACD momentum divergence: -0.15 histogram with MACD below signal line at price highs is a yellow flag warranting exposure reduction, not addition
• Zenbexus FDA approval catalyst already played out: 13.5% over 30 days, 38.1% over one year — buying after known catalyst is "buy the rumor, sell the news" trap in reverse
• Eliquis patent cliff 2027-2028 creates 12-14 billion dollar revenue hole; single Zenbexus asset is insufficient backfill — "enormous execution bet"
• Simply Wall St DCF showing 46% upside dismissed as screen-scraped model with sensitivity to assumptions — not a basis for adding risk
• Celgene lawsuit REINSTATED by federal appeals court: $6.7 billion exposure equals 40% of TTM free cash flow (~$8.25B) and 65% of $5.16B dividend run rate
• Q2 2026 EPS "growth" of 153% YoY is denominator engineering: comparison quarter had $1.6B restructuring and M&A charges
• PEG ratio of 2.26 not mentioned by aggressive analyst — growth expectations already priced into multiple
• Macro risks: 28% probability of Fed hike, oil up 36% YoY with Strait of Hormuz closed, Treasury buyback intervention not guaranteed
• Proposed trim: 30-40% reduction at $66, hard stop discipline, pharma sector cap at 60% of benchmark, retain 3.82% defensive yield
• Re-entry triggers anchored to mechanical levels: 50 SMA at $59.71 and 10 EMA at $64.50 — "textbook risk management," not manufactured
• Beta of 0.225 provides less upside and downside, but correlation to risk-off moves still exists

→ vs aggressive: MACD divergence at -0.15 histogram with MACD below signal line at price highs is not "just noise" — momentum divergence by definition precedes reversals, and prudent risk management means reducing exposure at yellow flags, not adding

→ vs aggressive: The $67.61 print from 2026-08-19 is from a raw CSV not included in the verified snapshot; verified close is $66.05 — building an aggressive add-on thesis on unverified data is speculation, not analysis

→ vs aggressive: Staged re-entry levels at 50 SMA ($59.71) and 10 EMA ($64.50) are mechanical, observable support levels with structural meaning — calling them "manufactured" is like calling a stop-loss manufactured

→ vs aggressive: Simply Wall St DCF showing 46% upside is a screen-scraped model sensitive to discount rate, terminal growth, and pipeline assumptions — the same model can show 46% upside or 30% downside depending on inputs

→ vs aggressive: Eliquis LOE is not just a 2027-2028 concern — equities price on expected cash flows, and proximity to patent cliff compresses multiples now; forward P/E of 10x reflects this overhang, and biosimilar entry means further compression, not less

→ vs aggressive: Celgene lawsuit dismissal as "tail risk" ignores that a federal appeals court REINSTATED the claims — this is a material adverse ruling, not routine procedure; even a half-settlement ($3.3B) equals 40% of TTM free cash flow

→ vs aggressive: Q2 2026 EPS growth of 153% YoY is comparing clean earnings against a depressed base with $1.6B in charges — this is denominator engineering, not operational acceleration, and the easy comp tailwind is already behind us

→ vs aggressive: The PEG of 2.26 was not mentioned by the Aggressive Analyst — a PEG above 2 for a company with base-effect-driven growth and pipeline execution risk suggests expectations are already in the multiple

→ vs aggressive: Macro "tailwind stack" of Fed hold (72%), oil gains, and Treasury buybacks has 28% Fed hike probability and could unwind quickly — defensive dividend payers like BMY are not immune to risk-off correlation

→ vs aggressive: The Aggressive Analyst's plan to add at 52-week highs into confirmed momentum divergence after known catalyst, with reinstated lawsuit in discovery and Eliquis biosimilars on 12-month horizon, is not aggressive — it is reckless

BUY (modified trim - reduce position 20-25% rather than 30-40%, retain majority long exposure with defined risk framework)

• Trim 20-25% instead of 30-40% - fundamentals (accelerating revenue, 1.57x FCF dividend coverage, FDA approval) warrant retaining majority position
• Replace inverted stop at $68.64 with trailing stop at 10 EMA around $64.50 to respect technical structure
• Citing 46% DCF upside from Simply Wall St is lazy analysis without knowing discount rate or terminal growth assumptions
• PEG of 2.26 indicates growth expectations already priced in - not a screaming bargain
• CVR lawsuit reinstatement is procedural ruling, not verdict - 40% of FCF math assumes worst-case settlement incorrectly
• FDA approval is first event in multi-year commercial story - Zenbexus quarterly sales uptake will be recurring catalyst for 8-12 quarters
• Macro is mildly supportive but not bulletproof - weakening dollar (25-30% non-US revenue) vs 28% Fed hike probability
• Re-entry zones at $63.90, $61.50, $59.71 are reasonable but need explicit policy if price never revisits them
• Both aggressive and conservative analysts are making market-timing bets disguised as risk management
• Formal Q3 earnings review recommended to reassess Zenbexus uptake before adding back

→ vs aggressive: Cherry-picks technical signals (uses upper Bollinger tag, ignores same oscillator's MACD divergence at minus 0.15); cites DCF without understanding assumptions; ignores PEG of 2.26; uses past 38% return to justify future returns circularly

→ vs conservative: Overstates CVR lawsuit (procedural ruling ≠ verdict on $6.7B); selectively dismisses raw CSV price of $67.61 but uses verified $66.05; misframes FDA approval as single binary event rather than multi-quarter commercial catalyst; treats growth expectations as already priced in